An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 020687
Company: DANCO LABS LLC

Medication Guide

Summary Review

REMS

Original REMS Approved in 2011

Other Important Information from FDA

Products on NDA 020687

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
MIFEPREX	MIFEPRISTONE	200MG	TABLET;ORAL	Prescription	AB	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 020687

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
09/28/2000	ORIG-1	Approval	Type 1 - New Molecular Entity	PRIORITY	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20687lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2000/20687appltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20687_mifepristone.cfm

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
03/23/2023	SUPPL-26	REMS - MODIFIED - D-N-A	Label (PDF) Letter (PDF) Review (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020687Orig1s026lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/020687Orig1s026ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/020687Orig1s026.pdf
01/03/2023	SUPPL-25	REMS - MODIFIED - D-N-A	Label (PDF) Letter (PDF) Review (PDF) Summary Review (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020687Orig1s025Lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/020687Orig1s025ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/020687Orig1s025.pdf https://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2023/020687Orig1s025SumR.pdf
05/14/2021	SUPPL-24	REMS - MODIFIED - D-N-A	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/020687Orig1s024ltr.pdf
08/05/2016	SUPPL-23	Manufacturing (CMC)		Label is not available on this site.
04/11/2019	SUPPL-22	REMS-Modified	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020687s022lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/020687Orig1s022ltr.pdf
03/10/2016	SUPPL-21	Manufacturing (CMC)		Label is not available on this site.
03/29/2016	SUPPL-20	Efficacy-New Dosing Regimen	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020687s020lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/020687Orig1s020ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/020687Orig1s020TOC.cfm
03/26/2013	SUPPL-19	Manufacturing (CMC)		Label is not available on this site.
04/24/2009	SUPPL-15	Labeling	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020687s015lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/020687s015ltr.pdf
06/08/2011	SUPPL-14	Labeling, REMS-Proposal	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020687s014lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/020687s014ltr.pdf
07/19/2005	SUPPL-13	Labeling	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020687s013lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/020687s013ltr.pdf
12/22/2004	SUPPL-11	Labeling	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/20687s011ltr.pdf
11/15/2004	SUPPL-10	Labeling	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/020687s010-lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/20687s010ltr.pdf
03/29/2002	SUPPL-1	Manufacturing (CMC)-Expiration Date		Label is not available on this site.

Labels for NDA 020687

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
03/23/2023	SUPPL-26	REMS - MODIFIED - D-N-A	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020687Orig1s026lbl.pdf
01/03/2023	SUPPL-25	REMS - MODIFIED - D-N-A	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020687Orig1s025Lbl.pdf
04/11/2019	SUPPL-22	REMS-Modified	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020687s022lbl.pdf
03/29/2016	SUPPL-20	Efficacy-New Dosing Regimen	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020687s020lbl.pdf
06/08/2011	SUPPL-14	Labeling	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020687s014lbl.pdf
06/08/2011	SUPPL-14	REMS-Proposal	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020687s014lbl.pdf
04/24/2009	SUPPL-15	Labeling	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020687s015lbl.pdf
07/19/2005	SUPPL-13	Labeling	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020687s013lbl.pdf
11/15/2004	SUPPL-10	Labeling	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/020687s010-lbl.pdf
09/28/2000	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20687lbl.pdf

Therapeutic Equivalents for NDA 020687

MIFEPREX

TABLET;ORAL; 200MG
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
MIFEPREX	MIFEPRISTONE	200MG	TABLET;ORAL	Prescription	Yes	AB	020687	DANCO LABS LLC
MIFEPRISTONE	MIFEPRISTONE	200MG	TABLET;ORAL	Prescription	No	AB	091178	GENBIOPRO

Top